RxDoctor Payments Data

Stephen Prater, MD

Clinical Cardiac Electrophysiology · Braselton, GANPI 1821097296

Payments from drug & device makers

$10,722in general payments, 2019–2025

Across 459 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$2K
  • Medtronic$1K
  • Pfizer$830
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$784
  • Novartis$456
  • plus $3K from 31 others

What the payments were for

  • Travel & lodging$1,08910%
  • Food & beverage$9,63390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,722 in reported general payments places this provider in the 20th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

See all clinical cardiac electrophysiology providers in Georgia

Medicare billing

Part B allowed, 2024
$362,997
Medicare patients
1,740
Services billed
5,696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban564$616,344
XareltoRivaroxaban147$198,951
EntrestoSacubitril/Valsartan21$18,733
Flecainide Acetate344$15,381
Dofetilide50$10,918
SotalolSotalol Hcl286$5,823
Metoprolol Succinate273$3,473
Diltiazem 24hr Er (Cd)Diltiazem Hcl143$3,245
Amiodarone Hcl181$3,242
Propafenone Hcl ErPropafenone Hcl15$2,258
Potassium Chloride71$1,346
ClopidogrelClopidogrel Bisulfate118$1,040
Losartan Potassium100$987
Midodrine Hcl20$963
Propafenone Hcl13$950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$830$616,344564 claims
Johnson & JohnsonXarelto$269$198,951147 claims
NovartisEntresto$456$18,73321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

Other clinical cardiac electrophysiology in Braselton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →